Hillman (NASDAQ:HLMN) Misses Q1 Revenue Estimates
Hardware products and merchandising solutions provider Hillman (NASDAQ:HLMN) missed Wall Street's revenue expectations in Q1 CY2025 as sales rose 2.6% year on year to $359.3 million. On the other hand, the company's full-year revenue guidance of $1.54 billion at the midpoint came in 0.5% above analysts' estimates. Its non-GAAP profit of $0.10 per share was in line with analysts' consensus estimates.
Is now the time to buy Hillman? Find out in our full research report.
Revenue: $359.3 million vs analyst estimates of $361.3 million (2.6% year-on-year growth, 0.5% miss)
Adjusted EPS: $0.10 vs analyst estimates of $0.10 (in line)
Adjusted EBITDA: $54.53 million vs analyst estimates of $54.15 million (15.2% margin, 0.7% beat)
The company reconfirmed its revenue guidance for the full year of $1.54 billion at the midpoint
EBITDA guidance for the full year is $265 million at the midpoint, above analyst estimates of $261.9 million
Operating Margin: 4.2%, in line with the same quarter last year
Free Cash Flow was -$21.31 million compared to -$6.08 million in the same quarter last year
Market Capitalization: $1.50 billion
"We got off to a good start during 2025, posting both top and bottom line growth which was driven by contributions from Intex DIY, which we acquired in August of 2024, and new business wins," commented Jon Michael Adinolfi, President and CEO of Hillman.
Established when Max Hillman purchased a franchise operation, Hillman (NASDAQ:HLMN) designs, manufactures, and sells industrial equipment and systems for various sectors.
A company's long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Regrettably, Hillman's sales grew at a sluggish 3.9% compounded annual growth rate over the last five years. This fell short of our benchmark for the industrials sector and is a tough starting point for our analysis.
We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. Hillman's recent performance shows its demand has slowed as its revenue was flat over the last two years.
This quarter, Hillman's revenue grew by 2.6% year on year to $359.3 million, falling short of Wall Street's estimates.
Looking ahead, sell-side analysts expect revenue to grow 4.9% over the next 12 months. Although this projection implies its newer products and services will catalyze better top-line performance, it is still below average for the sector.
Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Hillman was profitable over the last five years but held back by its large cost base. Its average operating margin of 3.7% was weak for an industrials business. This result is surprising given its high gross margin as a starting point.
On the plus side, Hillman's operating margin rose by 1.5 percentage points over the last five years, as its sales growth gave it operating leverage.
This quarter, Hillman generated an operating profit margin of 4.2%, in line with the same quarter last year. This indicates the company's cost structure has recently been stable.
Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.
Hillman's full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it's at a critical moment in its life.
Like with revenue, we analyze EPS over a shorter period to see if we are missing a change in the business.
Hillman's EPS grew at a spectacular 15.5% compounded annual growth rate over the last two years, higher than its flat revenue. This tells us management responded to softer demand by adapting its cost structure.
We can take a deeper look into Hillman's earnings to better understand the drivers of its performance. While we mentioned earlier that Hillman's operating margin was flat this quarter, a two-year view shows its margin has expanded by 3.9 percentage points. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals.
In Q1, Hillman reported EPS at $0.10, in line with the same quarter last year. This print beat analysts' estimates by 3.2%. Over the next 12 months, Wall Street expects Hillman's full-year EPS of $0.52 to grow 8.7%.
It was good to see Hillman provide full-year revenue and EBITDA guidance that slightly beat analysts' expectations. We were also glad its EBITDA slightly exceeded Wall Street's estimates, though its revenue slightly missed. Still, this quarter had some key positives. The stock remained flat at $7.56 immediately after reporting.
Should you buy the stock or not? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
- Composition of matter patent affirmed, provides protection into 2030 - Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 SAN DIEGO, June 09, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, holding that "a first filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date." "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for NUPLAZID, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for NUPLAZID 34 mg capsule formulation into 2038," said Catherine Owen Adams, Chief Executive Officer. "These decisions reinforce our commitment to safeguarding the intellectual property that underpins our innovations in addressing serious, unmet medical needs." This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its '721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," "continue" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the impact of the court ruling on our business and our ability to defend ourselves in the future; (ii) the continued patent protection for NUPLAZID; and (iii) the anticipated timing for termination of such protections. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our ability to maintain, protect and enhance our intellectual property; the outcome of other existing and potential future lawsuits challenging our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-Q for the quarter ended March 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law. View source version on Contacts Investor Contacts: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Inflation Cools, Jobs Steady--Is This the Market Rebound Investors Have Been Waiting For?
Consumer anxiety about rising prices may finally be easingand the timing could matter. According to fresh data from the New York Fed, Americans now see inflation coming in lower than they did just a month ago. Median year-ahead expectations dropped to 3.2% in May, down from 3.6% in April. Three- and five-year views also edged lower, now sitting at 3.0% and 2.6%, respectively. The shift follows a temporary de-escalation in trade tensions, with President Trump agreeing to reduce tariffs on Chinese imports. That announcement, while short-term, may have helped reverse the negative consumer sentiment that had been building since early this year. The job picture isn't boomingbut it might be stabilizing. Americans' perceived risk of losing their job over the next year ticked slightly lower, and more people say they feel confident enough to quit voluntarily. That's typically a positive signal for labor markets. At the same time, the share of households saying they expect to be financially worse off in a year has shrunk, and fewer respondents report difficulty accessing credit. Perhaps more telling: the average probability of missing a loan payment has dropped to its lowest point since Januaryhinting at some relief from financial stress, even as parts of the economy remain under pressure. This shift in sentiment may be influencing how people see the market. More consumers now expect the U.S. stock market to be higher a year from now. That optimism, combined with cooler inflation expectations and fewer job fears, could support short-term risk appetite heading into the summer. The Federal Reserve is widely expected to keep rates on pause at its upcoming June 1718 meeting, giving markets more room to digest the macro shifts. Tesla (NASDAQ:TSLA) and other high-beta names might see increased investor interest if this rebound in consumer confidence translates into steadier flows into equities. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Semtech (SMTC) Stock Trades Up, Here Is Why
Shares of semiconductor company Semtech (NASDAQ:SMTC) jumped 9.7% in the afternoon session after chip stocks rallied to start the week as investor optimism rose following trade discussions between U.S. and Chinese officials in London. Semiconductor companies have been among the hardest hit by the dispute, with key technologies subject to export controls. These restrictions have disrupted supply chains, creating uncertainty for both revenue growth and long-term planning. Following the talks, investor sentiment rebounded on expectations that some of these constraints may soon be lifted. U.S. National Economic Council Director Kevin Hassett reinforced this outlook, "Our expectation is that ... immediately after the handshake, any export controls from the U.S. will be eased, and the rare earths will be released in volume, and then we can go back to negotiating smaller matters.". The shares closed the day at $41.39, up 9.4% from previous close. Is now the time to buy Semtech? Access our full analysis report here, it's free. Semtech's shares are extremely volatile and have had 55 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 12 days ago when the stock dropped 6.8% on the news that the company reported underwhelming first quarter 2025 results: revenue was just in line this quarter, and revenue guidance for next quarter missed. On the other hand, Semtech reported a big improvement in inventory levels. Its adjusted operating income outperformed Wall Street's estimates. Still, this print was a mixed yet weaker quarter. Semtech is down 34.4% since the beginning of the year, and at $40.72 per share, it is trading 47.2% below its 52-week high of $77.15 from January 2025. Investors who bought $1,000 worth of Semtech's shares 5 years ago would now be looking at an investment worth $754.91. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio